Tricida Inc (NASDAQ:TCDA) Director Sells $126,759.60 in Stock

Tricida Inc (NASDAQ:TCDA) Director Klaus R. Dr Veitinger sold 3,492 shares of the business’s stock in a transaction on Friday, July 5th. The shares were sold at an average price of $36.30, for a total transaction of $126,759.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Shares of TCDA traded up $0.07 during trading hours on Tuesday, hitting $34.20. The stock had a trading volume of 260,471 shares, compared to its average volume of 307,514. The company’s fifty day moving average price is $36.42. The company has a debt-to-equity ratio of 0.24, a current ratio of 8.30 and a quick ratio of 8.30. Tricida Inc has a 52 week low of $19.43 and a 52 week high of $42.80. The stock has a market capitalization of $1.71 billion and a PE ratio of -7.37.

Tricida (NASDAQ:TCDA) last posted its earnings results on Wednesday, May 8th. The company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.10). On average, analysts anticipate that Tricida Inc will post -3.44 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its holdings in shares of Tricida by 59.2% in the 4th quarter. BlackRock Inc. now owns 1,600,579 shares of the company’s stock worth $37,743,000 after purchasing an additional 595,476 shares during the last quarter. FMR LLC grew its holdings in Tricida by 9.7% during the 1st quarter. FMR LLC now owns 1,213,065 shares of the company’s stock worth $46,849,000 after acquiring an additional 107,500 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Tricida by 40.1% during the 1st quarter. JPMorgan Chase & Co. now owns 1,014,195 shares of the company’s stock worth $39,169,000 after acquiring an additional 290,391 shares during the last quarter. Federated Investors Inc. PA grew its holdings in Tricida by 8.6% during the 1st quarter. Federated Investors Inc. PA now owns 443,100 shares of the company’s stock worth $17,113,000 after acquiring an additional 35,200 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Tricida by 8.5% during the 4th quarter. Geode Capital Management LLC now owns 188,925 shares of the company’s stock worth $4,454,000 after acquiring an additional 14,741 shares during the last quarter. 62.89% of the stock is currently owned by institutional investors and hedge funds.

TCDA has been the topic of several analyst reports. Empire upped their target price on shares of Tricida from $37.00 to $58.00 in a report on Monday, April 1st. Goldman Sachs Group initiated coverage on shares of Tricida in a report on Wednesday, June 26th. They issued a “buy” rating and a $48.00 target price on the stock. Needham & Company LLC initiated coverage on shares of Tricida in a report on Friday, May 24th. They issued a “buy” rating and a $50.00 target price on the stock. Cowen reaffirmed a “buy” rating and issued a $50.00 target price on shares of Tricida in a report on Tuesday, June 25th. Finally, Zacks Investment Research raised shares of Tricida from a “hold” rating to a “buy” rating and set a $42.00 target price on the stock in a report on Saturday, March 30th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $47.00.

Tricida Company Profile

Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.

See Also: How the Consumer Price Index (CPI) is calculated?

Insider Buying and Selling by Quarter for Tricida (NASDAQ:TCDA)

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.